Pharmacokinetics of isoxsuprine hydrochloride administered orally and intramuscularly to female healthy volunteers

Arzneimittel-Forschung/Drug Research

Volumn 59, Issue 9, 2009, Pages 455-460

  Marzo, Antonio ^a   Zava, Dario ^b   Coa, Katrin ^a   Dal Bo, Lorenzo ^a   Ismaili, Shefqet ^a   Tavazzi, Simona ^a   Cantoni, Vittorio ^b  

^a IPAS SA   (Switzerland)

^b Istituto Lusofarmaco d'Italia   (Italy)

Author keywords

CAS 395 28 8; Isoxsuprine, intramuscular absorption, oral absorption, pharmacokinetics, urinary excretion; Peripheral vasodilator; Vasosuprina

Indexed keywords

BETA ADRENERGIC RECEPTOR; CAS 395 28 8; ISOXSUPRINE; UNCLASSIFIED DRUG; VASOSUPRINA; VASOSUPRINA RETARD;

ADULT; AREA UNDER THE CURVE; ARTICLE; BEHAVIORAL SCIENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HEART RATE; HUMAN; INJECTION SITE BURNING; INJECTION SITE ERYTHEMA; INJECTION SITE HARDENING; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; STATISTICAL MODEL; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION;

EID: 70449671413     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296425     Document Type: Article

References (14)

1. Isoxsuprine hydrochloride. Martindale. The Complete Drug Reference. 35th ed. London: Pharmaceutical Press; 2007.
2. Kaindl F, Samuels SS, Selman D, Shaftel H. A new vasodilating and antispasmodic agent: isoxsuprine hydrochloride. Angiology. 1959 Aug;10:185-192
3. Di Perri T, Forconi S, Guerrini M, Pecchi S, Pieragalli D, Cappelli R, et al. Influence of non-selective and selective beta adrenoceptor blockade on isoxsuprine-dependent hemodynamic and rheologic changes. Angiology. 1981 Apr; 32:257-265
4. Salimbeni A, Manghisi E, Ferni G, Fregnan GB. Drug latentiation of isoxsuprine: synthesis and preliminary pharmacological activities of four monoesters. Farmaco [Sci]. 1983 Nov;38:904-910
5. Cohn JN. Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance. Circulation. 1973 Jul;48(1):5-8.
6. Gozo EG, Yebes RB. Hemodynamic effects of isoxsuprine in cardiac failure. Chest. 1984;86:736-740 (Pubitemid 15217648)
7. Lish PM, Dungan KW, Peters EL. A survey of the effects of isoxsuprine on nonvascular smooth muscle. J Pharmacol Exp Ther . 1960 Jun;129:191-199
8. Lish PM, Hillyard IW, Dungan KW. The uterine relaxant properties of isoxsuprine. J Pharmacol Exp Ther. 1960 Aug;129:438-444
9. Johnson WL McGaugey HS Jr, Thornton WN Jr. Effect of certain smooth muscle depressants on isolated human myometrial tissues. Am J Obstet Gynecol. 1963 Jun 1;86: 296-302.
10. Isoxsuprine hydrochloride. The Merck Index. 13th ed. Whitehouse Station (NJ): Merck & Co. Inc.; 2001.
11. Koh KS. Premature labour. Can Med Assoc J. 1976 Apr; 17:700-707
12. Calixto JB, Simas CM. Mechanism of action of isoprenaline, isoxsuprine, terbutaline and orciprenaline on gravid human isolated myometrium, Influence of the neuronal uptake process. Biol Reprod. 1984 Jun;30:1117-1123
13. Isoxsuprine hydrochloride. L'Informatore Farmaceutico. 25th ed. Milan (Italy): Elsevier Masson s. r. l.; 2008.
14. Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98; July 2001.